Table 3.
Objective response rate by crizotinib treatment
| Response | No. of Patients (%) | P-value | |
|---|---|---|---|
|
ALK + c-Met- (n = 101) |
ALK + c-Met+ (n = 15) |
||
| Complete response, n (%) | 0(0.0%) | 0(0.0%) | |
| Partial response, n (%) | 60(59.4%) | 13(86.7%) | |
| Stable disease, n (%) | 25(24.8%) | 2(13.3%) | |
| Progressive disease, n (%) | 16(15.8%) | 0(0.0%) | |
| ORR, % | 59.4% | 86.7% | 0.041 |
| DCR, % | 84.2% | 100% | 0.126 |
Abbreviations: ALK anaplastic lymphoma kinase, c-Met cellular-mesenchymal-epithelial transition, ALK + c-Met+ patients with ALK rearrangement and c-Met overexpression positive, ALK + c-Met- patients with ALK rearrangement and c-Met overexpression negative